ClinicalTrials.gg
CompletedNCT00139594Updated Mar 28, 2017

Open Label Extension Study of Licarbazepine in the Treatment of Manic Episodes of Bipolar I Disorder

A Phase 4 interventional study of licarbazepine in Bipolar Disorder, sponsored by Novartis. Completed at 44 sites in 13 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2017-03-28.

Sponsored by Novartis · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
181
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 837 studies in Bipolar Disorder with a site in United States — 77 open to participants now, 96 under way, 8 of them phase 3. Bipolar Disorder · United States.

Enrollment
148th of 704
181 · median 58
Started
2004
with 41 others
Phase 4
155 of 837
8 open now
Registered
76th of 837
by date

Among the 837 studies in Bipolar Disorder with a site in United States, this one is the 148th largest by enrollment of the 704 interventional ones that give a count, is one of 42 that started in 2004, is one of 155 in phase 4, and was the 76th registered.

Bipolar Disorder

1,686 studies on the registry are indexed under Bipolar Disorder; 268 are open to participants now.

Browse Bipolar Disorder studies →

Open to participants now

77 of the 837 studies in Bipolar Disorder with a site in United States are open now. Recruiting first, the newest first:

72 more — sign in →

All 77 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 208 Bipolar Disorder studies recruiting now, 59 (28%) set no upper age limit and 136 (65%) stop at 75 or younger; 38 take children under 18; 51 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 837 studies in Bipolar Disorder with a site in United States, or all of them as a file.
02

Study summary

This extension study is designed to assess the long-tem tolerability and safety of licarbazepine in patients who completed the 6-week double-blind study CLIC477D2303.

03

Conditions studied

  • Bipolar Disorder

Keywords

  • Bipolar disorder, manic episode/treatment/licarbazepine
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • written provided prior to participation in the extension study
  • successful completion of study CLIC477D2303
  • cooperation and willingness to comply with all study requirements

Exclusion criteria

Exclusion Criteria:

  • premature discontinuation from study CLIC477D2303
  • failure to comply with study CLIC477D2303
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
181 participants (actual)

Study arms

  • Experimental
    licarbazepine

    Drug: licarbazepine

Interventions

06

What researchers measure

Primary outcomes

  1. Safety and tolerability of treatment with licarbazepine over 52 weeks.

  2. with respect to the rates of adverse events and serious adverse events, as well as changes in laboratory values, ECGs and vital signs.

07

Study locations

44 sites
  • Investigational site
    La Palma, California 20623, United States
  • Novartis Investigational Site
    Kansas City, Kansas, United States
  • Novartis Investigational Site
    Shreveport, Louisiana, United States
  • Novartis Investigational Site
    Somerville, Massachusetts, United States
  • Novartis Investigational Site
    Farmington Hills, Michigan, United States
  • Novartis Investigational Site
    Staten Island, New York, United States
  • Novartis Investigational Site
    Madison, Tennessee, United States
  • Novartis Investigational Site
    Bellaire, Texas, United States
  • Novartis Investigational Site
    Dallas, Texas, United States
  • Novartis Investigational Site
    Verdun, Texas, United States
  • Novartis Investigational Site
    Bellevue, Washington, United States
  • Novartis Investigational Site
    Kirkland, Washington, United States
  • Novartis Investigational site
    West Allis, Wisconsin, United States
  • Novartis Investigational Site
    Vienna, Austria
  • Novartis Investigational Site
    Kelowna, Canada
  • Novartis Investigational Site
    London, Canada
  • Novartis Investigational Site
    Montreal, Canada
  • Novartis Investigational Site
    Sudbury, Canada
  • Novartis Investigator Site
    Vancouver, Canada
  • Novartis Investigational Site
    Bogota, Colombia
  • Novartis Investigational Site
    Medellin, Colombia
  • Novartis Investigational Site
    Pareira, Colombia
  • Novartis Investigational Site
    Brno, Czech Republic
  • Novartis Investigational Site
    Hradec Kralove, Czech Republic
  • Novartis Investigational Site
    Prague, Czech Republic
  • Novartis Investigational Site
    Berlin, Germany
  • Novartis Investigational Site
    Bochum, Germany
  • Novartis Investigational Site
    Dresden, Germany
  • Novartis Investigational Site
    Ingolstadt, Germany
  • Novartis Investigational Site
    Mannheim, Germany
  • Novartis Investigational Site
    Wurzburg, Germany
  • Novartis Investigational Site
    Guatemala City, Guatemala
  • Novartis Investigational Site
    Lima, Peru
  • Novartis Investigational Site
    Moscow, Russian Federation
  • Novartis Investigational Site
    Yaroslavl, Russian Federation
  • Novartis Investigational Site
    Bojnice, Slovakia
  • Novartis Investigational Site
    Michalovce, Slovakia
  • Novartis Investigational Site
    Durban, South Africa
  • Novartis Investigational Site
    Dnepropetrovsk, Ukraine
  • Novartis Investigational Site
    Kiev, Ukraine
  • Novartis Investigational Site
    Lugansk, Ukraine
  • Novartis Investigational Site
    Odessa, Ukraine
  • Novartis Investigational Site
    Simferopol, Ukraine
  • Novartis Investigational Site
    Caracas, Venezuela
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2004, a primary completion of Jul 2007 and a completion of Jul 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 29, 2005
First posted
Aug 31, 2005
Start
Dec 2004
Primary completionActual
Jul 2007
CompletionActual
Jul 2007
Last update
Mar 28, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 28, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00139594
Lead sponsor
Novartis
Responsible party
Sponsor
First posted
Aug 31, 2005
Start date
Dec 2004
Primary completion
Jul 2007
Completion
Jul 2007
Last update
Mar 28, 2017

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Licarbazepine

Start the discussion